The Value of Intravenous Iron: Beyond the Cave of Speculation.

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2020-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2019121340PMID 32253272PMCID PMC7217414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.

  2020cited by this paper
• Intravenous Iron in Patients Undergoing Maintenance Hemodialysis

  2019cited by this paper
• Intravenous Iron Use in the Care of Patients with Kidney Disease.

  2019cited by this paper
• Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis

  2018cited by this paper
• Considerations and challenges in defining optimal iron utilization in hemodialysis.

  2015cited by this paper
• Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.

  2012cited by this paper
• Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.

  2009cited by this paper
• Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

  2007cited by this paper
• Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.

  2007cited by this paper
• Iron treatment: impact of safety issues.

  1998cited by this paper

• Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients

  2022cites this paper
• Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO.

  2021cites this paper
• Intravenous iron in heart failure and chronic kidney disease.

  2021cites this paper
• Intravenous iron in heart failure and chronic kidney disease.

  2020cites this paper
• Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.

  2020cites this paper
• Clinical perspectives on the treatment of renal anemia with HIF stabilizers

  2020cites this paper
• A new insight into the treatment of renal anemia with HIF stabilizer

  2020cites this paper
• Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?

  2020cites this paper
• Iron deficiency and iron therapy in heart failure and chronic kidney disease.

  2020cites this paper